Developer docs
API playgroundTry for free, no card

Search company profiles

Hillo

Full company profile

uuid0003pbr

Namestring
Hillo
Legal namestring
Hillo
Websiteurl
hillo.ai
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Hillo is a French health technology company that develops an AI-based digital twin platform for precision diabetes care, with a primary focus on Type 1 Diabetes patients using continuous glucose monitoring (CGM) devices. The company operates two products from a single underlying engine: a web application for healthcare providers that performs behavioral pattern analysis, therapeutic habit extraction, and in-silico treatment simulation, and a patient-facing real-time blood glucose prediction capability delivered through an API integrated into third-party logbook applications. The digital twin models are trained on real-world patient datasets from observational trials conducted in France and clinical trials from reference centers in Europe and the US, and the company reports prediction accuracy of 99.9%, 98.6%, and 96.3% within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons.

The business model is a dual B2B and B2B2C structure: HCP web application access follows an enterprise subscription/recurring licensing motion (evidenced by a "Request a Demo" call-to-action), while the patient prediction engine is monetized through API licensing into partner logbook applications. Target customers are endocrinologists, diabetes specialists, and other HCPs managing complex T1D cases, with end-patients reached indirectly through clinical recommendation or embedded app deployment. The company was co-founded by Stéphane Bidet (CEO) and Nicolas Caleca (CSO), with Pr. Eric Renard (Head of Endocrinology, Lapeyronie University Hospital) serving as clinical advisor since 2017. Hillo has raised approximately $2.37M across seed and early-stage rounds led by NCI Waterstart and has built partnerships with Bpifrance, Microsoft for Startups, NVIDIA Inception, École Polytechnique, HEC Paris, and various French innovation hubs. The company has been acquired by Stēto and now operates within the Stēto group under steto.care.

Short descriptiontext

Hillo is a French AI healthtech company that builds digital twin technology for Type 1 Diabetes management, offering a clinical decision support web app for healthcare providers and a real-time blood glucose prediction API for patient logbook applications, now operating within the Stēto group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIgny, France
HQ citystring
Igny
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes management software, digital twin technology, blood glucose prediction, clinical decision support, AI diabetes care
Industry3 codes
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Diabetes Management Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1HCP Web Application Licensing
TypeSubscription Recurring
Description

B2B licensing of the web application platform to healthcare providers (HCPs) for clinical decision support in diabetes management. The platform enables HCPs to analyze patient data, simulate treatment changes, and develop personalized treatment plans.

hillo.ai
2Patient API Integration
TypeLicensing Royalties
Description

API-based integration of the prediction engine into patient-facing logbook applications, enabling real-time blood glucose prediction and personalized recommendations for preventive actions.

hillo.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Hillo develops an AI-based digital twin platform that builds patient-specific glycemic models from continuous glucose monitoring (CGM), insulin dosing, and meal data. It sells two offerings: (1) a web application for healthcare providers that performs ML-driven glycemic pattern analysis, therapeutic habit extraction, and in-silico treatment simulation to optimize diabetes management plans, and (2) a real-time blood glucose prediction API integrated into patient-facing logbook applications that delivers personalized preventive recommendations to patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Prediction accuracy up to 99.9%, 98.6%, and 96.3% of computed blood glucose values within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons
+2 more records
Product overview1 text field

Hillo offers a dual-product portfolio centered on AI-based digital twin technology for precision diabetes care. The core offering consists of: (1) Hillo for HCPs – a web application for healthcare providers that uses ML algorithms to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico simulation; and (2) Hillo for Patients – a real-time blood glucose prediction capability integrated into patient-facing logbook applications through the Hillo API. Both products are powered by a proprietary digital twin engine trained on real-world patient data that simulates glycemic response to insulin dosage and meal timing adjustments.

Product and service2 records
1Hillo for HCPs (Web Application)
CategoryClinical Decision Support Software
Description

Web application for healthcare providers that uses ML to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico digital twin simulation; designed for endocrinologists and diabetes specialists managing Type 1 Diabetes patients on CGM.

2Hillo for Patients (Real-Time Blood Glucose Prediction API)
CategoryPatient Prediction API
Description

API-based real-time blood glucose prediction capability integrated into patient-facing logbook applications; uses Hillo's digital twin to predict glucose direction and risk of hypo/hyperglycemia and deliver personalized preventive recommendations to Type 1 Diabetes patients using CGM.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Future4care is a partner organization shown in Hillo's partners section. Future4care appears to be a health-tech accelerator or innovation hub based in France.

2AI for Health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

AI for Health is listed as a partner. The organization appears to focus on AI applications in healthcare, aligning with Hillo's diabetes management technology.

hillo.ai
Strategic tierCoreTypeTechnology or Integration
Description

Hillo participates in Microsoft for Startups program, providing access to Azure cloud infrastructure and Microsoft technology stack integration.

Strategic tierCoreTypeTechnology or Integration
Description

Hillo is part of NVIDIA's startup program, providing access to GPU computing resources and technical support for AI/ML model development.

Strategic tierModerateTypeStrategic or Co-development Partner
Description

École Polytechnique (France's leading engineering school) is listed as a partner, likely providing research collaboration and talent access.

Strategic tierModerateTypeStrategic or Co-development Partner
Description

HEC Paris (leading business school) is listed as a partner, potentially providing business strategy support, talent, and entrepreneurship resources.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Paris & Co is Paris's agency for business and innovation support, providing incubation and acceleration services.

8Agoranov
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Agoranov is a French startup incubator providing support services to early-stage technology companies.

hillo.ai
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital health platform offering disease-management software for diabetes and related cardiometabolic conditions, with EHR-integrated decision support. Comparable as a chronic disease management software company with a clinical decision support offering for diabetes providers.

TypeBroad incumbent
Description

Maker of insulin pumps and the t:slim X2 automated insulin delivery system with embedded bolus calculator and prediction algorithms. Comparable as a Type 1 diabetes device-and-software player that combines hardware with clinical decision support, and a potential partner or competitor for Hillo's prediction engine.

TypeBroad incumbent
Description

Leading CGM device maker expanding into decision-support software, including the Dexcom Clarity analytics platform. Comparable because it owns the upstream CGM data pipeline Hillo depends on and increasingly competes in the HCP analytics and patient prediction layer.

TypeDirect peer
Description

Digital health platform combining a CGM-connected app, AI-based glucose prediction, and coaching for diabetes management. Directly comparable as an AI-driven diabetes prediction and self-management product with both consumer and B2B components.

TypeDirect peer
Description

Diabetes self-management logbook app and decision support platform acquired by Roche, offering CGM data integration, bolus advice, and patient coaching. Directly comparable as a consumer-facing diabetes app with a B2B2C model and HCP-facing tools.

TypeDirect peer
Description

Diabetes data management platform that aggregates CGM, pump, and logbook data and offers HCP-facing analytics and patient-facing apps. Directly comparable as a diabetes data platform with both an HCP clinical dashboard and consumer logbook product, competing for the same workflow.

TypeDirect peer
Description

French company developing an AI-based closed-loop insulin delivery system with embedded glucose prediction algorithms for Type 1 diabetes. Highly comparable French/European competitor operating in the same AI-driven diabetes management category with similar clinical evidence positioning.

TypeEmerging player
Description

Provider of insulin dosing decision support software (Glucommander) for hospitals and outpatient settings. Comparable as an AI-based clinical decision support company for insulin dosing with enterprise sales to providers, although its primary focus is inpatient rather than T1D ambulatory care.

TypeEmerging player
Description

Developer of the iLet bionic pancreas, an automated insulin delivery system using algorithmic dosing decisions. Comparable as a competing AI-driven dosing approach in Type 1 diabetes; potential complement or alternative to Hillo's digital twin technology.

TypeBroad incumbent
Description

Maker of the Omnipod tubeless insulin pump with embedded bolus calculator and SmartAdjust automated insulin delivery technology. Comparable as a Type 1 diabetes device-plus-software company with embedded dose decision support, serving overlapping endocrinology and patient segments.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hillo

Diabetes Management Softwarehillo.ai

Hillo is a French AI healthtech company that builds digital twin technology for Type 1 Diabetes management, offering a clinical decision support web app for healthcare providers and a real-time blood glucose prediction API for patient logbook applications, now operating within the Stēto group.

What Hillo does

Hillo is a French health technology company that develops an AI-based digital twin platform for precision diabetes care, with a primary focus on Type 1 Diabetes patients using continuous glucose monitoring (CGM) devices. The company operates two products from a single underlying engine: a web application for healthcare providers that performs behavioral pattern analysis, therapeutic habit extraction, and in-silico treatment simulation, and a patient-facing real-time blood glucose prediction capability delivered through an API integrated into third-party logbook applications. The digital twin models are trained on real-world patient datasets from observational trials conducted in France and clinical trials from reference centers in Europe and the US, and the company reports prediction accuracy of 99.9%, 98.6%, and 96.3% within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons.

The business model is a dual B2B and B2B2C structure: HCP web application access follows an enterprise subscription/recurring licensing motion (evidenced by a "Request a Demo" call-to-action), while the patient prediction engine is monetized through API licensing into partner logbook applications. Target customers are endocrinologists, diabetes specialists, and other HCPs managing complex T1D cases, with end-patients reached indirectly through clinical recommendation or embedded app deployment. The company was co-founded by Stéphane Bidet (CEO) and Nicolas Caleca (CSO), with Pr. Eric Renard (Head of Endocrinology, Lapeyronie University Hospital) serving as clinical advisor since 2017. Hillo has raised approximately $2.37M across seed and early-stage rounds led by NCI Waterstart and has built partnerships with Bpifrance, Microsoft for Startups, NVIDIA Inception, École Polytechnique, HEC Paris, and various French innovation hubs. The company has been acquired by Stēto and now operates within the Stēto group under steto.care.

Hillo firmographics

Firmographics
Name
Hillo
Legal name
Hillo
Website
https://hillo.ai
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Hillo is a French AI healthtech company that builds digital twin technology for Type 1 Diabetes management, offering a clinical decision support web app for healthcare providers and a real-time blood glucose prediction API for patient logbook applications, now operating within the Stēto group.
Ownership category
akta.pro rank

Hillo industry classification

Industry
Product category
Diabetes Management Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Diabetes management software
  • Digital twin technology
  • Blood glucose prediction
  • Clinical decision support
  • AI diabetes care

Where Hillo is headquartered

Location

Headquarters

HQ city
Igny
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Hillo business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. HCP Web Application Licensing: B2B licensing of the web application platform to healthcare providers (HCPs) for clinical decision support in diabetes management. The platform enables HCPs to analyze patient data, simulate treatment changes, and develop personalized treatment plans.
  2. Patient API Integration: API-based integration of the prediction engine into patient-facing logbook applications, enabling real-time blood glucose prediction and personalized recommendations for preventive actions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Hillo product offering

Product offering

Core offering

Hillo develops an AI-based digital twin platform that builds patient-specific glycemic models from continuous glucose monitoring (CGM), insulin dosing, and meal data. It sells two offerings: (1) a web application for healthcare providers that performs ML-driven glycemic pattern analysis, therapeutic habit extraction, and in-silico treatment simulation to optimize diabetes management plans, and (2) a real-time blood glucose prediction API integrated into patient-facing logbook applications that delivers personalized preventive recommendations to patients.

Product overview

Hillo offers a dual-product portfolio centered on AI-based digital twin technology for precision diabetes care. The core offering consists of: (1) Hillo for HCPs – a web application for healthcare providers that uses ML algorithms to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico simulation; and (2) Hillo for Patients – a real-time blood glucose prediction capability integrated into patient-facing logbook applications through the Hillo API. Both products are powered by a proprietary digital twin engine trained on real-world patient data that simulates glycemic response to insulin dosage and meal timing adjustments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hillo for HCPs (Web Application) Web application for healthcare providers that uses ML to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico digital twin simulation; designed for endocrinologists and diabetes specialists managing Type 1 Diabetes patients on CGM.
  • Hillo for Patients (Real-Time Blood Glucose Prediction API) API-based real-time blood glucose prediction capability integrated into patient-facing logbook applications; uses Hillo's digital twin to predict glucose direction and risk of hypo/hyperglycemia and deliver personalized preventive recommendations to Type 1 Diabetes patients using CGM.

Quantifiable outcome

  • Prediction accuracy up to 99.9%, 98.6%, and 96.3% of computed blood glucose values within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons
  • +2 more outcomes

Companies that use Hillo

Customer profile

Segments2 records

Ideal customer profiles2 records

Hillo technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Hillo partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, moderate and minor.

  • future4carecoreStrategic or Co-development PartnerFuture4care is a partner organization shown in Hillo's partners section. Future4care appears to be a health-tech accelerator or innovation hub based in France.
  • AI for HealthcoreStrategic or Co-development PartnerAI for Health is listed as a partner. The organization appears to focus on AI applications in healthcare, aligning with Hillo's diabetes management technology.
  • Microsoft for StartupscoreTechnology or IntegrationHillo participates in Microsoft for Startups program, providing access to Azure cloud infrastructure and Microsoft technology stack integration.
  • NVIDIA InceptioncoreTechnology or IntegrationHillo is part of NVIDIA's startup program, providing access to GPU computing resources and technical support for AI/ML model development.
  • École PolytechniquemoderateStrategic or Co-development PartnerÉcole Polytechnique (France's leading engineering school) is listed as a partner, likely providing research collaboration and talent access.
  • HEC ParismoderateStrategic or Co-development PartnerHEC Paris (leading business school) is listed as a partner, potentially providing business strategy support, talent, and entrepreneurship resources.
  • Paris & CominorStrategic or Co-development PartnerParis & Co is Paris's agency for business and innovation support, providing incubation and acceleration services.
  • AgoranovminorStrategic or Co-development PartnerAgoranov is a French startup incubator providing support services to early-stage technology companies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Hillo competitors and assessment

Company assessment

Emerging players

  • Rimidi: Digital health platform offering disease-management software for diabetes and related cardiometabolic conditions, with EHR-integrated decision support. Comparable as a chronic disease management software company with a clinical decision support offering for diabetes providers.
  • Glytec: Provider of insulin dosing decision support software (Glucommander) for hospitals and outpatient settings. Comparable as an AI-based clinical decision support company for insulin dosing with enterprise sales to providers, although its primary focus is inpatient rather than T1D ambulatory care.
  • Beta Bionics: Developer of the iLet bionic pancreas, an automated insulin delivery system using algorithmic dosing decisions. Comparable as a competing AI-driven dosing approach in Type 1 diabetes; potential complement or alternative to Hillo's digital twin technology.

Broad incumbents

  • Tandem Diabetes Care: Maker of insulin pumps and the t:slim X2 automated insulin delivery system with embedded bolus calculator and prediction algorithms. Comparable as a Type 1 diabetes device-and-software player that combines hardware with clinical decision support, and a potential partner or competitor for Hillo's prediction engine.
  • Dexcom: Leading CGM device maker expanding into decision-support software, including the Dexcom Clarity analytics platform. Comparable because it owns the upstream CGM data pipeline Hillo depends on and increasingly competes in the HCP analytics and patient prediction layer.
  • Insulet: Maker of the Omnipod tubeless insulin pump with embedded bolus calculator and SmartAdjust automated insulin delivery technology. Comparable as a Type 1 diabetes device-plus-software company with embedded dose decision support, serving overlapping endocrinology and patient segments.

Direct peers

  • One Drop: Digital health platform combining a CGM-connected app, AI-based glucose prediction, and coaching for diabetes management. Directly comparable as an AI-driven diabetes prediction and self-management product with both consumer and B2B components.
  • mySugr (Roche): Diabetes self-management logbook app and decision support platform acquired by Roche, offering CGM data integration, bolus advice, and patient coaching. Directly comparable as a consumer-facing diabetes app with a B2B2C model and HCP-facing tools.
  • Glooko: Diabetes data management platform that aggregates CGM, pump, and logbook data and offers HCP-facing analytics and patient-facing apps. Directly comparable as a diabetes data platform with both an HCP clinical dashboard and consumer logbook product, competing for the same workflow.
  • Diabeloop: French company developing an AI-based closed-loop insulin delivery system with embedded glucose prediction algorithms for Type 1 diabetes. Highly comparable French/European competitor operating in the same AI-driven diabetes management category with similar clinical evidence positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Hillo social profiles

Digital presence

Hillo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hillo leadership team

Management profile

Number of profiles

Profiles3 records

Hillo funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hillo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hillo

What does Hillo do?

Hillo develops an AI-based digital twin platform that builds patient-specific glycemic models from continuous glucose monitoring (CGM), insulin dosing, and meal data. It sells two offerings: (1) a web application for healthcare providers that performs ML-driven glycemic pattern analysis, therapeutic habit extraction, and in-silico treatment simulation to optimize diabetes management plans, and (2) a real-time blood glucose prediction API integrated into patient-facing logbook applications that delivers personalized preventive recommendations to patients.

Is Hillo a public or private company?

Hillo is a private company. It is classified as corporate owned and is currently operating.

When was Hillo founded?

Hillo was founded in 2016. It employs 11 to 50 people.

Where is Hillo based?

Hillo is headquartered in Igny, France, in the Europe region.

How does Hillo make money?

Two revenue lines are on record. HCP Web Application Licensing is the primary driver. The others are patient API Integration.

Who are Hillo's main competitors?

Emerging players on record are Rimidi, Glytec and Beta Bionics. Broad incumbents are Tandem Diabetes Care, Dexcom and Insulet. Direct peers are One Drop, mySugr (Roche), Glooko and Diabeloop.

Does Hillo have an API?

Yes. Hillo provides an API for patient-facing integration. The API enables real-time blood glucose prediction, allowing patients to receive personalized recommendations for preventive actions when they don't know the direction of their glucose levels or whether they are at risk of hypo or hyperglycemia. The digital twin technology powers predictions to help patients avoid anticipated glycemic excursions. Integrated into a logbook app through the API.

What industry is Hillo in?

Hillo's product category is Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales